The oxidation and hypoglycaemic effect of sorafenib in streptozotocin-induced diabetic rats

BACKGROUND: Diabetes reduces the activity of CYP3A4 and may increase the exposure for the drugs metabolized by the isoenzyme. Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI), used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine resist...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pharmacol Rep
Main Authors: Karbownik, Agnieszka, Stachowiak, Anna, Urjasz, Hanna, Sobańska, Katarzyna, Szczecińska, Agnieszka, Grabowski, Tomasz, Stanisławiak-Rudowicz, Joanna, Wolc, Anna, Grześkowiak, Edmund, Szałek, Edyta
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2020
Assuntos:
Short Communication
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8187206/
https://ncbi.nlm.nih.gov/pubmed/32016844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s43440-019-00021-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares